Literature DB >> 29141219

Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.

Jin Lee1, Rui Liao2, Gaowei Wang1, Bi-Huei Yang3, Xiaolin Luo1, Nissi M Varki1, Shuang-Jian Qiu4, Bing Ren5, Wenxian Fu3, Gen-Sheng Feng6.   

Abstract

Liver cancer has become the second most deadly malignant disease, with no efficient targeted or immune therapeutic agents available yet. While dissecting the roles of cytoplasmic signaling molecules in hepatocarcinogenesis using an inducible mouse gene targeting system, Mx1-cre, we identified a potent liver tumor-inhibitory effect of synthetic double-stranded RNA (dsRNA), polyinosinic-polycytidylic acid (pIC), an inducer of the Mx1-cre system. Injection of pIC at the pre-cancer stage robustly suppressed liver tumorigenesis either induced by chemical carcinogens or by Pten loss and associated hepatosteatosis. The immunostimulatory dsRNA inhibited liver cancer initiation, apparently by boosting multiple anti-tumor activities of innate immunity, including induction of immunoregulatory cytokines, activation of NK cells and dendritic cells, and reprogramming of macrophage polarization. This study paves the way for the development of preventive and early interfering strategies for liver cancer to reduce the rapidly increasing incidences of liver cancer in an ever-growing population with chronic liver disorders.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  dsRNA; immunotherapy; innate immune system; liver cancer; liver tumor-initiating cells; macrophage polarization; preventive therapy

Mesh:

Substances:

Year:  2017        PMID: 29141219      PMCID: PMC5737819          DOI: 10.1016/j.celrep.2017.10.064

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  34 in total

1.  Toll-like receptor signaling pathways.

Authors:  Gregory M Barton; Ruslan Medzhitov
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

Review 2.  A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Authors:  Maurizio Brausi; J Alfred Witjes; Donald Lamm; Raj Persad; Joan Palou; Marc Colombel; Roger Buckley; Mark Soloway; Hideyuki Akaza; Andreas Böhle
Journal:  J Urol       Date:  2011-10-19       Impact factor: 7.450

Review 3.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

4.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

Review 5.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.

Authors:  Jessica Zucman-Rossi; Augusto Villanueva; Jean-Charles Nault; Josep M Llovet
Journal:  Gastroenterology       Date:  2015-06-20       Impact factor: 22.682

6.  The role of JNK in the development of hepatocellular carcinoma.

Authors:  Madhumita Das; David S Garlick; Dale L Greiner; Roger J Davis
Journal:  Genes Dev       Date:  2011-03-15       Impact factor: 11.361

7.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 8.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.

Authors:  Weiping Zou; Jedd D Wolchok; Lieping Chen
Journal:  Sci Transl Med       Date:  2016-03-02       Impact factor: 17.956

9.  Immunomodulation by imiquimod in patients with high-risk primary melanoma.

Authors:  Rupa Narayan; Hong Nguyen; Jason J Bentow; Lauren Moy; Diana K Lee; Stephanie Greger; Jacquelyn Haskell; Veena Vanchinathan; Pei-Lin Chang; Shanli Tsui; Tamiko Konishi; Begonya Comin-Anduix; Christine Dauphine; Hernan I Vargas; James S Economou; Antoni Ribas; Kevin W Bruhn; Noah Craft
Journal:  J Invest Dermatol       Date:  2011-08-18       Impact factor: 8.551

10.  EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.

Authors:  Hanane Lanaya; Anuradha Natarajan; Karin Komposch; Liang Li; Nicole Amberg; Lei Chen; Stefanie K Wculek; Martina Hammer; Rainer Zenz; Markus Peck-Radosavljevic; Wolfgang Sieghart; Michael Trauner; Hongyang Wang; Maria Sibilia
Journal:  Nat Cell Biol       Date:  2014-08-31       Impact factor: 28.824

View more
  13 in total

Review 1.  Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Clin Cancer Res       Date:  2020-04-23       Impact factor: 12.531

2.  An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice.

Authors:  Liang Wen; Bing Xin; Panyisha Wu; Chia-Hao Lin; Chuanhui Peng; Gaowei Wang; Jin Lee; Li-Fan Lu; Gen-Sheng Feng
Journal:  Hepatology       Date:  2019-03-13       Impact factor: 17.425

3.  Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.

Authors:  Wendy S Chen; Yan Liang; Min Zong; Jacey J Liu; Kota Kaneko; Kaisa L Hanley; Kun Zhang; Gen-Sheng Feng
Journal:  Cell Rep       Date:  2021-11-09       Impact factor: 9.423

4.  Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.

Authors:  Bing Xin; Meixiang Yang; Panyisha Wu; Li Du; Xingyu Deng; Enfu Hui; Gen-Sheng Feng
Journal:  Hepatology       Date:  2022-01-23       Impact factor: 17.298

Review 5.  Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics.

Authors:  Haichuan Wang; Xin Chen; Diego F Calvisi
Journal:  Expert Opin Ther Targets       Date:  2021-09-11       Impact factor: 6.797

6.  DCK is an Unfavorable Prognostic Biomarker and Correlated With Immune Infiltrates in Liver Cancer.

Authors:  Shu Fang Hu; Xia Lin; Lv Ping Xu; Hong Gang Chen; Ju Feng Guo; Li Jin
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 7.  Mouse Models for Immunotherapy in Hepatocellular Carcinoma.

Authors:  Enya Li; Li Lin; Chia-Wei Chen; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2019-11-15       Impact factor: 6.639

Review 8.  Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer.

Authors:  Yongyan Chen; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2020-10-12       Impact factor: 11.530

Review 9.  Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.

Authors:  Gen-Sheng Feng; Kaisa L Hanley; Yan Liang; Xiaoxue Lin
Journal:  Hepatology       Date:  2020-11-08       Impact factor: 17.425

Review 10.  Genetically Engineered Mouse Models for Liver Cancer.

Authors:  Kyungjoo Cho; Simon Weonsang Ro; Sang Hyun Seo; Youjin Jeon; Hyuk Moon; Do Young Kim; Seung Up Kim
Journal:  Cancers (Basel)       Date:  2019-12-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.